Loading market movers...

Tarlatamab

Phase 3

Amgen Inc. (AMGN)

00%

Orphan DrugFast TrackBreakthrough TherapyLearn about designations

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

AMGNPhase 2$219.9B

Tarlatamab Phase 2 Est. Readout

Tarlatamab• Small Cell Lung Cancer32

BTDFTOrphan

Q3 2027~QConfirmed

00%

Oct '26

AMGNPhase 2$219.9B

Tarlatamab Phase 2 Est. Readout

Tarlatamab• Small Cell Lung Cancer40

BTDFTOrphan

Oct 2026~Confirmed

00%

Competitive Landscape

5 competitors in Small Cell Lung Cancer

MRKIfinatamab Deruxtecan

View Full Landscape

Drug Information

Target Indication

Small Cell Lung Cancer

Mechanism of Action

BiTE (DLL3xCD3)

Clinical Trial

Last updated: 12/3/2025

Patent & Exclusivity

No Patent Data

Application

Source: FDA Orange Book

Regulatory Approvals

EMA5/29/2026

Imdylltra

Imdylltra is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.

Orphan

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

PegaspargasePhase 3

Acute Lymphoblastic Leukemia

Etanercept LiquidPhase 3

Rheumatoid Arthritis

romosozumab HCP administration with PFSPhase 3

Post-Menopausal Osteoporosis

AMG 162 / DenosumabPhase 3

Breast Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts